These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16518941)

  • 1. [Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
    MMW Fortschr Med; 2006 Feb; 148(5):48-9. PubMed ID: 16518941
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschr Med; 2006 May; 148(18):42-3. PubMed ID: 16736689
    [No Abstract]   [Full Text] [Related]  

  • 4. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
    MMW Fortschr Med; 2003 Oct; 145(43):51. PubMed ID: 14664222
    [No Abstract]   [Full Text] [Related]  

  • 5. [Convincing results from the JIKEI Study].
    MMW Fortschr Med; 2006 Dec; 148(51-52):55. PubMed ID: 17619349
    [No Abstract]   [Full Text] [Related]  

  • 6. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VALIANT trial results support use of valsartan in acute myocardial infarction.
    Cardiovasc J S Afr; 2004; 15(1):45, 47. PubMed ID: 15095754
    [No Abstract]   [Full Text] [Related]  

  • 10. Valsartan, captopril, or both in myocardial infarction.
    McAnulty JH
    N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
    [No Abstract]   [Full Text] [Related]  

  • 11. Heart attack patients with complications. Treat with valsartan, captopril, or both?
    Nguyen A; Sharma S
    Can Fam Physician; 2004 Aug; 50():1093-5. PubMed ID: 15455807
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiotensin II type 1 receptor blockers and congestive heart failure.
    Auer JW; Berent R; Eber B
    Circulation; 2001 Oct; 104(15):E82. PubMed ID: 11591633
    [No Abstract]   [Full Text] [Related]  

  • 13. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract]   [Full Text] [Related]  

  • 15. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM; Hilkert R
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sartans for hypertension--implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
    Cheung BM
    Hong Kong Med J; 2004 Oct; 10(5):359. PubMed ID: 15479968
    [No Abstract]   [Full Text] [Related]  

  • 17. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension.
    Minami J; Ohno E; Furukata S; Ishimitsu T; Matsuoka H
    J Hum Hypertens; 2009 Oct; 23(10):683-6. PubMed ID: 19369955
    [No Abstract]   [Full Text] [Related]  

  • 18. [New options against undertreatment].
    Pfeffer M
    MMW Fortschr Med; 2003 Dec; 145(49):18. PubMed ID: 14963987
    [No Abstract]   [Full Text] [Related]  

  • 19. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M
    Heart Fail Monit; 2002; 2(3):85-7. PubMed ID: 12634889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
    Majahalme SK; Baruch L; Aknay N; Goedel-Meinen L; Hofmann M; Hester A; Prescott MF; Feliciano N;
    Am J Cardiol; 2005 Feb; 95(4):529-32. PubMed ID: 15695147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.